Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?
Goebell P, Bedke J (2015)
Publication Type: Journal article, Editorial
Publication year: 2015
Journal
Book Volume: 46
Pages Range: 473-80
Journal Issue: 6
Abstract
The introduction of molecular targeted agents has started to transform the treatment of metastatic renal cell carcinoma (mRCC), leading to a significant improvement of the prognosis of patients affected by that disease. However, treatment of metastatic disease still remains challenging as almost all patients will experience tumour progression and long-term survivors are very rare. This clearly warrants a continued search for improved treatment options. In recent years, the development of new substances and treatment approaches involving the targeted activation and modulation of the immune system have moved immunotherapy back into the focus of interest. A major development is the use of checkpoint inhibitors, which enable a targeted (re)activation of T cells. The following article describes the current methods used to improve standard treatment with the established targeted substances and discusses them along with the new immunooncological approaches of checkpoint modulation in the context of the treatment of mRCC patients.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Goebell, P., & Bedke, J. (2015). Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now? Aktuelle Urologie, 46(6), 473-80. https://doi.org/10.1055/s-0041-106138
MLA:
Goebell, Peter, and J. Bedke. "Molecular Concepts of Immunomodulation for the Treatment of Metastatic Renal Cell Carcinomas: Where are We Now?" Aktuelle Urologie 46.6 (2015): 473-80.
BibTeX: Download